Bivalent human papilloma virus vaccine (Cervarix) in the treatment of cutaneous warts

Abstract

Background: Bivalent human papilloma virus (HPV) vaccine has a successful effect in therapy of recalcitrant cutaneous warts. The purpose of this study was to assess the efficacy and safety of intralesional (IL) injection of bivalent HPV vaccine (cervarix) versus IL saline in therapy of recalcitrant cutaneous warts.

Methods: Forty-four patients with resistant warts to therapy were classified into 2 groups; 22 patients in each group. Group A was received Cervarix vaccine 0.1ml into the biggest wart 2-weeks apart and group B (control) was received IL saline. The patients in both groups received sessions until the patients achieved complete clearance or for a five sessions. .

Results: One month after the treatment, 86.4% of patients achieved complete response in group A (IL cervarix vaccine) versus to 4.2 % of the control (group B) with a highly significant difference (P <0.0001). No recurrence was reported in patients with complete response. The side effects were mild tolerated pain during the injection.

Conclusion: IL cervarix vaccine can be used as a safe treatment modality for the therapy of resistant warts.